News
ITCI
127.12
+0.09%
0.11
Steady M&A Deals To Begin 2025, Disappointing IPOs So Far
Seeking Alpha · 10h ago
Weekly Report: what happened at ITCI last week (0203-0207)?
Weekly Report · 1d ago
Morgan Stanley Remains a Hold on Intra-Cellular Therapies (ITCI)
TipRanks · 5d ago
INTRA-CELLULAR THERAPIES INC <ITCI.O>: UBS RAISES TARGET PRICE TO $132 FROM $87
Reuters · 6d ago
U.S. RESEARCH ROUNDUP-Alphabet, Amgen, SSR Mining
Reuters · 6d ago
Weekly Report: what happened at ITCI last week (0127-0131)?
Weekly Report · 02/03 09:24
Intra-Cellular Therapies Price Target Raised to $132.00/Share From $119.00 by Canaccord Genuity
Dow Jones · 01/31 10:33
Intra-Cellular Therapies Cut to Hold From Buy by Canaccord Genuity
Dow Jones · 01/31 10:33
Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold, Raises Price Target to $132
Benzinga · 01/31 10:23
INTRA-CELLULAR THERAPIES INC <ITCI.O>: CANACCORD GENUITY CUTS TO HOLD FROM BUY; RAISES TARGET PRICE TO $132 FROM $119
Reuters · 01/31 05:52
Intra-Cellular downgraded to Hold from Buy at Canaccord
TipRanks · 01/30 22:55
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
Seeking Alpha · 01/30 22:03
J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)
TipRanks · 01/29 12:08
How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance
NASDAQ · 01/27 20:00
Weekly Report: what happened at ITCI last week (0120-0124)?
Weekly Report · 01/27 09:24
INTRA-CELLULAR THERAPIES INC <ITCI.O>: JP MORGAN RAISES TARGET PRICE TO $132 FROM $89
Reuters · 01/27 07:36
BUZZ-Street View: New drug launches, ITCI deal to boost J&J's growth
Reuters · 01/23 12:00
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
Benzinga · 01/22 21:00
Intra-Cellular Therapies Price Target Raised to $132.00/Share From $108.00 by RBC Capital
Dow Jones · 01/22 17:17
More
Webull provides a variety of real-time ITCI stock news. You can receive the latest news about Intra-Cellular Therapies through multiple platforms. This information may help you make smarter investment decisions.
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.